Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients.
Papantoniou D, Fröss-Baron K, Garske-Román U, Sundin A, Thiis-Evensen E, Grönberg M, Welin S, Tiensuu Janson E. Papantoniou D, et al. J Neuroendocrinol. 2024 Mar 13:e13379. doi: 10.1111/jne.13379. Online ahead of print. J Neuroendocrinol. 2024. PMID: 38477040
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms.
Laskaratos FM, Armeni E, Shah H, Megapanou M, Papantoniou D, Hayes AR, Navalkissoor S, Gnanasegaran G, von Stempel C, Phillips E, Furnace M, Kamieniarz L, Kousteni M, Luong TV, Watkins J, Mandair D, Caplin M, Toumpanakis C. Laskaratos FM, et al. Among authors: papantoniou d. Endocrine. 2020 Jan;67(1):233-242. doi: 10.1007/s12020-019-02086-6. Epub 2019 Sep 25. Endocrine. 2020. PMID: 31556004 Free PMC article.
Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours.
Laskaratos FM, Walker M, Wilkins D, Tuck A, Ramakrishnan S, Phillips E, Gertner J, Megapanou M, Papantoniou D, Shah R, Banks J, Vlachou E, Garcia-Hernandez J, Woodbridge L, Papadopoulou A, Grant L, Theocharidou E, Watkins J, Luong TV, Mandair D, Caplin M, Toumpanakis C. Laskaratos FM, et al. Among authors: papantoniou d. Neuroendocrinology. 2018;107(3):292-304. doi: 10.1159/000493317. Epub 2018 Aug 28. Neuroendocrinology. 2018. PMID: 30153671
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Holmsten K, Eknert J, Öfverholm E, Papantoniou D, Jawdat F, Verbiéné I, Laurell A, Jänes E, Sandzén J, Wojtyna-Dziedzic E, Lagstam I, Söderkvist K, Costa Svedman F, Liedberg F, Bruzelius M, Fransson AS, Kjellström S, Omland LH, Pappot H, Ullén A. Holmsten K, et al. Among authors: papantoniou d. Clin Genitourin Cancer. 2023 Dec;21(6):e438-e448. doi: 10.1016/j.clgc.2023.05.008. Epub 2023 May 17. Clin Genitourin Cancer. 2023. PMID: 37308329 Free article.
Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study.
Rezazadeh Kalebasty A, Benjamin DJ, Loriot Y, Papantoniou D, Siefker-Radtke AO, Necchi A, Naini V, Carcione JC, Santiago-Walker A, Triantos S, Burgess EF. Rezazadeh Kalebasty A, et al. Among authors: papantoniou d. Eur Urol Open Sci. 2022 Dec 15;47:48-57. doi: 10.1016/j.euros.2022.11.001. eCollection 2023 Jan. Eur Urol Open Sci. 2022. PMID: 36601039 Free PMC article.
17 results